Outcomes in patients >/= 80 years with a diagnosis of a hepatopancreaticobiliary (HPB) malignancy
AuthorsLewis, Alexandra R
Hubner, Richard A
Valle, Juan W
McNamara, Mairead G
AffiliationThe Christie NHS Foundation Trust, Manchester, UKUniversity of Manchester Medical School, Manchester, UK
MetadataShow full item record
AbstractOlder patients are underrepresented in oncological clinical trials. The incidence of hepatopancreaticobiliary (HPB) malignancies is higher in older patients, but data on outcomes are lacking. This study assessed patient outcomes in those?<?80 and?³?80 years with a HPB malignancy seen at a tertiary referral centre, The Christie NHS Foundation Trust. Data on patients with a HPB malignancy were collected retrospectively between 2012 and 2017 via on-line case-note review. Survival was calculated using the Kaplan-Meier method and prognostic factors using log-rank analysis. Of 1421 patients, 10% were?³?80 years. Of patients?<?80 and?³?80 years, 56% and 57% had pancreas cancer, 39% and 36% biliary tract cancer, and 5% and 7% had hepatocellular carcinoma, respectively. Amongst patients?³?80 years, 75% had an Eastern Cooperative Oncology Group performance status (ECOG PS) 0-2. Patients?³?80 years had higher rates of comorbidity; 28% received systemic anti-cancer therapy (SACT), compared with 62% of patients?<?80 years. Best supportive care (BSC) was instituted in 44% of older patients, compared with 13% in those?<?80 years. Of patients?³?80 years who received SACT, 82% received monotherapy. Median overall survival (OS) for patients receiving palliative SACT was 10.07 months (95% CI 8.89-11.08) and 10.10 months (95% CI 6.30-12.30) in patients?<?80 and?³?80 years, respectively, p 0.41; ECOG PS (p?<?0.001) was prognostic for OS in older patients but Adult Comorbidity Evaluation-27 comorbidity score (p?=?0.07, when comparing groups of ACE score?²?1 and?>?1) was not. Baseline factors were similar in both age cohorts, but more comorbidities were present in older patients. Older patients were less likely to receive SACT, but when they did, they had an equivalent benefit in OS to younger patients.
CitationLewis AR, Cipriano C, Wang X, Ward R, Fitzpatrick A, Scott ARM, et al. Outcomes in patients >/= 80 years with a diagnosis of a hepatopancreaticobiliary (HPB) malignancy. Med Oncol. 2019 Sep 6;36(10):85.
- Impact of palliative chemotherapy and best supportive care on overall survival and length of hospitalization in patients with incurable Cancer: a 4-year single institution experience in Japan.
- Authors: Murakawa Y, Sakayori M, Otsuka K
- Issue date: 2019 Jun 3
- Clinical Outcomes in Elderly Patients Treated for Oral Cavity Squamous Cell Carcinoma.
- Authors: Chen JJ, Shah JL, Harris JP, Bui TT, Schaberg K, Kong CS, Kaplan MJ, Divi V, Schoppy D, Le QT, Hara WY
- Issue date: 2017 Jul 15
- Palliative chemotherapy for gastroesophageal cancer in old and very old patients: A retrospective cohort study at the National Center for Tumor Diseases, Heidelberg.
- Authors: Berger AK, Zschaebitz S, Komander C, Jäger D, Haag GM
- Issue date: 2015 Apr 28
- The G8 screening tool enhances prognostic value to ECOG performance status in elderly cancer patients: A retrospective, single institutional study.
- Authors: Takahashi M, Takahashi M, Komine K, Yamada H, Kasahara Y, Chikamatsu S, Okita A, Ito S, Ouchi K, Okada Y, Imai H, Saijo K, Shirota H, Takahashi S, Mori T, Shimodaira H, Ishioka C
- Issue date: 2017
- Survival Analysis of Advanced Non-Small Cell Lung Cancer Patients Treated by Using Wheel Balance Cancer Therapy.
- Authors: Kim J, Cho CK, Yoo HS
- Issue date: 2016 Dec